Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $48.86 and last traded at $47.68, with a volume of 237795 shares trading hands. The stock had previously closed at $47.79.
Gemini Therapeutics Trading Up 0.6 %
The firm’s fifty day moving average is $47.02 and its 200 day moving average is $43.41. The company has a market cap of $2.06 billion, a PE ratio of -47.65 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
- Five stocks we like better than Gemini Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- How Much Can You Make in Stocks in One Month?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- This Is the Top Large-Cap Stock Insiders Are Buying
- Investing in Commodities: What Are They? How to Invest in Them
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
